Novo Nordisk is Denmark’s big little problem

As war rages and Donald Trump looms, a recent election featured little mention of the ailing $164 bln drugmaker, once so successful it distorted economic figures. In this week’s Viewsroom, Breakingviews columnists discuss the future of weight loss pills, and Novo’s place in it. Novo Nordisk's illness offers painful lessons Novo Nordisk’s falling knife is still gathering speed Obesity pills are shaky Hail Mary for Novo Nordisk Visit the Thomson Reuters Privacy Statement for information on our privacy and data protection practices. You may also visit megaphone.fm/adchoices to opt-out of targeted advertising. Learn more about your ad choices. Visit megaphone.fm/adchoices